Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity

被引:0
|
作者
K J Wernli
P A Newcomb
J M Hampton
A Trentham-Dietz
K M Egan
机构
[1] Cancer Prevention Program,Department of Cancer Control
[2] Fred Hutchinson Cancer Research Center,Department of Risk Assessment
[3] 1100 Fairview Avenue N,undefined
[4] University of Wisconsin Paul P Carbone Comprehensive Cancer Center,undefined
[5] Detection,undefined
[6] and Intervention,undefined
[7] H Lee Moffitt Cancer Center and Research Institute,undefined
来源
British Journal of Cancer | 2008年 / 98卷
关键词
ovarian cancer; non-steroidal anti-inflammatory drugs; parity; oral contraceptives;
D O I
暂无
中图分类号
学科分类号
摘要
We examined the association between non-steroidal anti-inflammatory drug (NSAID) use and ovarian cancer by potential effect modifiers, parity and oral contraceptive use, in a population-based case–control study conducted in Wisconsin and Massachusetts. Women reported prior use of NSAIDs and information on risk factors in a telephone interview. A total of 487 invasive ovarian cancer cases and 2653 control women aged 20–74 years were included in the analysis. After adjustment for age, state of residence and other covariates, ever use of NSAIDs was inversely associated with ovarian cancer in never users of oral contraceptives (odds ratio (OR)=0.58, 95% confidence interval (CI) 0.42–0.80) but not for ever users (OR=0.98, 95% CI 0.71–1.35) (P-interaction=0.03). A reduced risk with NSAID use was also noted in nulliparous women (OR=0.47, 95% CI 0.27–0.82) but not among parous women (OR=0.81, 95% CI 0.64–1.04) (P-interaction=0.05). These results suggest that use of NSAIDs were beneficial to women at greatest risk for ovarian cancer.
引用
收藏
页码:1781 / 1783
页数:2
相关论文
共 50 条
  • [1] Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity
    Wernli, K. J.
    Newcomb, P. A.
    Hampton, J. M.
    Trentham-Dietz, A.
    Egan, K. M.
    BRITISH JOURNAL OF CANCER, 2008, 98 (11) : 1781 - 1783
  • [2] Declining ovarian cancer rates in US women in relation to parity and oral contraceptive use
    Gnagy, S
    Ming, EE
    Devesa, SS
    Hartge, P
    Whittemore, AS
    EPIDEMIOLOGY, 2000, 11 (02) : 102 - 105
  • [3] Timing of births and oral contraceptive use influences ovarian cancer risk
    Wu, Anna H.
    Pearce, Celeste Leigh
    Lee, Alice W.
    Tseng, Chiuchen
    Jotwani, Anjali
    Patel, Prusha
    Pike, Malcolm C.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (12) : 2392 - 2399
  • [4] Family history of cancer, oral contraceptive use, and ovarian cancer risk
    Walker, GR
    Schlesselman, JJ
    Ness, RB
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (01) : 8 - 14
  • [5] Oral contraceptive use in relation to smoking
    Morabia, A
    Bernstein, M
    Bleed, D
    Campana, A
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1998, 77 (02) : 205 - 209
  • [6] Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer
    Faber, M. T.
    Jensen, A.
    Frederiksen, K.
    Glud, E.
    Hogdall, E.
    Hogdall, C.
    Blaakaer, J.
    Kjaer, S. K.
    CANCER CAUSES & CONTROL, 2013, 24 (12) : 2197 - 2206
  • [7] An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use
    Anna S. Avramenko
    James M. Flanagan
    Clinical Epigenetics, 15
  • [8] Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer
    M. T. Faber
    A. Jensen
    K. Frederiksen
    E. Glud
    E. Høgdall
    C. Høgdall
    J. Blaakær
    S. K. Kjær
    Cancer Causes & Control, 2013, 24 : 2197 - 2206
  • [9] An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use
    Avramenko, Anna S.
    Flanagan, James M.
    CLINICAL EPIGENETICS, 2023, 15 (01)
  • [10] Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
    Tsilidis, K. K.
    Allen, N. E.
    Key, T. J.
    Dossus, L.
    Lukanova, A.
    Bakken, K.
    Lund, E.
    Fournier, A.
    Overvad, K.
    Hansen, L.
    Tjonneland, A.
    Fedirko, V.
    Rinaldi, S.
    Romieu, I.
    Clavel-Chapelon, F.
    Engel, P.
    Kaaks, R.
    Schuetze, M.
    Steffen, A.
    Bamia, C.
    Trichopoulou, A.
    Zylis, D.
    Masala, G.
    Pala, V.
    Galasso, R.
    Tumino, R.
    Sacerdote, C.
    Bueno-de-Mesquita, H. B.
    van Duijnhoven, F. J. B.
    Braem, M. G. M.
    Onland-Moret, N. C.
    Gram, I. T.
    Rodriguez, L.
    Travier, N.
    Sanchez, M-J
    Huerta, J. M.
    Ardanaz, E.
    Larranaga, N.
    Jirstrom, K.
    Manjer, J.
    Idahl, A.
    Ohlson, N.
    Khaw, K-T
    Wareham, N.
    Mouw, T.
    Norat, T.
    Riboli, E.
    BRITISH JOURNAL OF CANCER, 2011, 105 (09) : 1436 - 1442